<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03035331</url>
  </required_header>
  <id_info>
    <org_study_id>MC1685</org_study_id>
    <secondary_id>NCI-2017-00113</secondary_id>
    <secondary_id>MC1685</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03035331</nct_id>
  </id_info>
  <brief_title>Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma</brief_title>
  <official_title>Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the best dose and side effects of dendritic cell therapy,
      cryosurgery and pembrolizumab in treating patients with non-Hodgkin lymphoma. Vaccines, such
      as dendritic cell therapy made from a person's tumor cells and white blood cells may help the
      body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells
      by freezing them. Monoclonal antibodies, such as pembrolizumab, may interfere with the
      ability of tumor cells to grow and spread. Giving dendritic cell therapy, cryosurgery and
      pembrolizumab may work better at treating non-Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate the optimal dose schedule, safety and tolerability as measured by the incidence
      of significant toxicity of combination therapy with anti-PD-1 monoclonal antibody,
      cryoablation, and intra-tumor injection of autologous dendritic cell into the cryoablated
      tumor. (Phase I) II. Test the efficacy (overall response rate) of combination therapy with
      anti-PD-1 monoclonal antibody, cryoablation, and intra-tumor injection of autologous
      dendritic cell vaccine. (Phase II)

      SECONDARY OBJECTIVES:

      I. Evaluate the feasibility of this combination immunotherapy. (Phase I) II. Evaluate patient
      quality of life. (Phase I) III. Evaluate the partial response (PR) and complete response (CR)
      rate of this combination immunotherapy. (Phase II) IV. Evaluate the progression free
      survival, treatment free survival, duration of response, disease-free rate at 2 years, and
      overall survival of this combination immunotherapy. (Phase II) V. Evaluate the safety of this
      combination immunotherapy. (Phase II)

      TERTIARY OBJECTIVES:

      I. Assess the effect of combination immunotherapy on patients' immune status and anti-tumor
      immune response.

      II. Assess the potential association between PD-1/PD-L1/PD-L2 expression in tumor and blood
      with clinical efficacy.

      III. Assess the potential association between tumor antigen mutations and antigen-specific
      immune response with clinical efficacy.

      IV. Evaluate patient quality of life.

      OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

      Patients receive pembrolizumab intravenously (IV) on day 1. Treatment repeats every 21 days
      for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients
      also receive dendritic cell therapy intratumorally (IT) on days 2, 8, and 15 of courses 2 and
      3, and day 2 of courses 4 and 5. Patients undergo cryosurgery on day 2 of course 2 and
      receive pneumococcal 13-valent conjugate vaccine by injection on day 2 of courses 2-5.
      Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up every 4 months during the
      second year post-treatment, and then every 6 months for up to 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    per study design
  </why_stopped>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Anticipated">February 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) defined as the dose level that does not induce dose limiting toxicity in at least one-third of patients</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Measured by the incidence of significant toxicity of combination therapy with anti-PD-1 monoclonal antibody, cryoablation, and intra-tumor injection of autologous dendritic cell into the cryoablated tumor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of complete responses of combination therapy with pembrolizumab, cryoablation, and intra-tumor injection of autologous DC at MTD dose</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated. The response rate will be calculated, in each individual cohort as supplementary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival rate</measure>
    <time_frame>At 2 years</time_frame>
    <description>The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated. The response rate will be calculated, in each individual cohort as supplementary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The distribution of duration of complete response will be estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The maximum grade for each type of adverse event at each evaluation will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. Longitudinal analysis techniques will be utilized to determine the effect of time on treatment adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From registration to death due to any cause, assessed up to 2 years</time_frame>
    <description>The distribution of survival time will be estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The distribution of survival time will be estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured using the Functional Assessment of Cancer Therapy-lymphoma</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The assessment will be scored according to the scoring algorithm. Changes from baseline will be calculated at each assessment time points. Mean change scores at each time point will be calculated to determine if quality of life is reduced over the course of treatment. Longitudinal techniques will be employed to describe changes over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment free survival</measure>
    <time_frame>From registration to next treatment or death due to any cause, assessed up to 4 years</time_frame>
    <description>The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in immunologic correlates</measure>
    <time_frame>Baseline up to 4 years</time_frame>
    <description>Will be evaluated and summarized both quantitatively and graphically. Each of the correlative endpoints will be summarized individually, but will also be evaluated in terms of their relationships to one another; i.e., will use Spearman rank correlation coefficient to assess the correlations between baseline levels as well as between changes before and after treatment in these immunologic markers. In addition, these immunologic markers will be correlated with cancer and treatment- related outcomes (e.g. response, toxicities). Relationships will also be explored graphically using scatter plots.</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiologic analysis</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Measurements of index lesion(s) (non-cryoablated lesion) will be evaluated over time for each patient as a marker of systemic immune and treatment response to pembrolizumab and localized treatment with cryoablation and dendritic cell therapy. The index lesion(s) will be selected by the treating physician/investigator and are noncryoablated node. The percent change from baseline in index lesion measurements will be assessed over time. Differences in values over time will be summarized descriptively and graphically. The whole body computed tomography (CT) or positron emission tomography/CT will</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Aggressive Non-Hodgkin Lymphoma</condition>
  <condition>Indolent Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Diffuse Large B-Cell Lymphoma</condition>
  <condition>Recurrent Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma</condition>
  <condition>Recurrent T-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients also receive dendritic cell therapy IT on days 2, 8, and 15 of courses 2 and 3, and day 2 of courses 4 and 5. Patients undergo cryosurgery on day 2 of course 2 and receive pneumococcal 13-valent conjugate vaccine by injection on day 2 of courses 2-5. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryosurgery</intervention_name>
    <description>Undergo cryosurgery</description>
    <arm_group_label>Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)</arm_group_label>
    <other_name>CRYOABLATION</other_name>
    <other_name>cryosurgical ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic Cell Therapy</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)</arm_group_label>
    <other_name>Dendritic Cell Vaccine Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal 13-valent Conjugate Vaccine</intervention_name>
    <description>Given by injection</description>
    <arm_group_label>Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)</arm_group_label>
    <other_name>PCV 13</other_name>
    <other_name>PCV13 Vaccine</other_name>
    <other_name>Prevnar 13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of biopsy-proven non-Hodgkin lymphoma, excluding chronic
             lymphocytic leukemia, primary central nervous system (CNS) lymphoma and Burkitt's
             lymphoma; Note: small lymphocytic lymphoma (SLL) is allowed

          -  Patients with indolent non-Hodgkin lymphoma (NHL) must have had &gt;= 1 regimen of
             rituximab-containing regimen; Note: this includes follicular lymphoma (FL), marginal
             lymphoma and mucosa-associated lymphoid tissue (MALT)

          -  Patient with aggressive NHL must have received prior therapy - at a minimum:

               -  Anti-CD20 monoclonal antibody unless tumor is CD20 negative and

               -  An anthracycline containing regimen

               -  Transformed FL must have had therapy for FL and be refractory to chemotherapy for
                  DLBCL

          -  Chemotherapy refractory disease in aggressive NHL is defined as

               -  Stable disease of =&lt; 12 months or progressive disease as best response to most
                  recent chemotherapy containing regimen

               -  Disease progression or recurrence =&lt; 12 months of prior autologous stem cell
                  transplantation (SCT)

          -  Patients with aggressive NHL must have failed autologous hematopoietic stem cell
             transplantation (HSCT), or are ineligible or not consenting to autologous HSCT

          -  Patient must have at least 3 measurable lesions that are &gt;= 1.5 cm in one dimension;
             one of the lesions must be &gt;= 2.0 cm and is amenable to image-guided cryoablation and
             multiple vaccine injections as determined by interventional radiology and principal
             investigator (PI) (including tumors that can be safely accessed using imaging guidance
             and treated with minimal risk to adjacent structures)

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2

          -  Absolute neutrophil count (ANC) &gt;= 1000/mm3

          -  Absolute lymphocyte count &gt;= 500/mm3

          -  Platelet count &gt;= 75,000/mm3

          -  Hemoglobin &gt;= 8.0 g/dL

          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN), unless due to Gilbert's disease

          -  Aspartate transaminase (AST/serum glutamic-oxaloacetic transaminase [SGOT]) and
             alanine transaminase (ALT/serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 x ULN

          -  Creatinine =&lt; 1.5 x ULN or calculated creatinine clearance &gt;= 60 mL/min for subject
             with creatinine Ëƒ 1.5 x institutional ULN

          -  Negative serum pregnancy test for women of childbearing potential =&lt; 7 days prior to
             registration; Note: a second pregnancy test may be required =&lt; 72 hours prior to
             receiving the first dose of study medication

          -  Negative human immunodeficiency virus (HIV), hepatitis B and C, and tuberculosis (TB)
             test

          -  Provide written informed consent

          -  Willing to return to the enrolling institution for follow-up (during active treatment
             and active monitoring phase of the study)

          -  Ability to complete questionnaire(s) by themselves or with assistance

          -  Willing to provide tissue and blood samples for research purposes

          -  Willing to use adequate contraception while on the study and until 120 days after the
             last dose of study drug

        Exclusion Criteria:

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          -  Serious non-malignant disease such as active infection, symptomatic congestive heart
             failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
             situations or other conditions which in the opinion of the investigator would
             compromise protocol objectives

          -  Currently receiving or have received any other investigational agent considered as a
             treatment for the primary neoplasm =&lt; 28 days or within 4 half-lives (whichever is
             shorter) of the agent prior to registration

          -  History of other primary malignancy requiring systemic treatment within 6 months of
             protocol enrollment; patients must not be receiving chemotherapy or immunotherapy for
             another cancer; patients must not have another active malignancy requiring active
             treatment with the following acceptable EXCEPTIONS:

               -  Basal cell carcinoma, squamous cell carcinoma, or melanoma of the skin that has
                  undergone or will undergo potentially curative therapy

               -  In situ cervical cancer that has undergone or will undergo potentially curative
                  therapy

          -  Prior allogeneic bone marrow or peripheral blood stem cell transplantation

          -  Prior autologous bone marrow or peripheral blood stem cell transplantation =&lt; 100 days
             prior to registration or if recovery from the transplant is inadequate

          -  Major surgery other than diagnostic surgery =&lt; 4 weeks prior to registration

          -  Prior chemotherapy or radiation therapy =&lt; 2 weeks prior to registration or who has
             not recovered (i.e. to =&lt; grade 1 or baseline) from an adverse event due to the
             previously administered therapy

          -  History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any
             component of the formulation, including diphtheria toxoid

          -  Active autoimmune disease such as Crohn's disease, rheumatoid arthritis, Sjogrens'
             disease, systemic lupus erythematosis, or similar conditions requiring systemic
             treatment within the past 3 months or a documented history of clinically severe
             autoimmune disease/syndrome difficult to control in the past

               -  EXCEPTIONS:

                    -  Vitiligo or resolved childhood asthma/atopy

                    -  Intermittent use of bronchodilators or local steroid injections

                    -  Hypothyroidism stable on hormone replacement,

                    -  Diabetes stable with current management

                    -  History of positive Coombs test but no evidence of hemolysis

                    -  Psoriasis not requiring systemic treatment

                    -  Conditions not expected to recur in the absence of an external trigger

          -  Coagulopathy, including the use of Coumadin or heparin anticoagulants that cannot be
             discontinued for the cryoablation procedure; NOTE: heparin for line patency without
             detectable lab abnormalities for coagulation will be allowed

          -  Corticosteroid use =&lt; 2 weeks prior to registration; NOTE: patients must be off
             corticosteroids for at least 2 weeks prior to registration; this includes oral, IV,
             subcutaneous, or inhaled route of administration; patients on chronic corticosteroid
             for adrenal insufficiency or other reasons may enroll if they receive less than 10
             mg/day of prednisone (or equivalent)

          -  Active CNS malignancy

          -  Evidence of interstitial lung disease or active, non-infectious pneumonitis

          -  Received a live vaccine =&lt; 30 days prior to registration

          -  New York Heart Association classification III or IV cardiovascular disease or recent
             myocardial infarction or unstable angina pectoris or cardiac arrhythmia =&lt; 30 days
             prior to registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Lin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2017</study_first_submitted>
  <study_first_submitted_qc>January 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

